1
|
Leung CC, Yu IT and Chen W: Silicosis.
Lancet. 379:2008–2018. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Greenberg MI, Waksman J and Curtis J:
Silicosis: A review. Dis Mon. 53:394–416. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mossman BT and Churg A: Mechanisms in the
pathogenesis of asbestosis and silicosis. Am J Respir Crit Care
Med. 157:1666–1680. 1998. View Article : Google Scholar : PubMed/NCBI
|
4
|
Castranova V and Vallyathan V: Silicosis
and coal workers' pneumoconiosis. Environ Health Perspect.
108:675–684. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Thomas CR and Kelley TR: A brief review of
silicosis in the United States. Environ Health Insights.
4:212010.PubMed/NCBI
|
6
|
Cohen RA, Patel A and Green FH: Lung
disease caused by exposure to coal mine and silica dust. Semin
Respir Crit Care Med. 29:651–661. 2008. View Article : Google Scholar
|
7
|
Sirajuddin A and Kanne JP: Occupational
lung disease. J Thorac Imaging. 24:310–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Rimal B, Greenberg AK and Rom WN: Basic
pathogenetic mechanisms in silicosis: Current understanding. Curr
Opin Pulm Med. 11:169–173. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Davis GS: Pathogenesis of silicosis:
Current concepts and hypotheses. Lung. 164:139–154. 1986.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Yucesoy B, Vallyathan V, Landsittel DP,
Simeonova P and Luster MI: Cytokine polymorphisms in silicosis and
other pneumoconioses. Mol Cell Biochem. 234:219–224. 2002.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Vanhée D, Gosset P, Boitelle A, Wallaert B
and Tonnel A: Cytokines and cytokine network in silicosis and coal
workers' pneumoconiosis. Eur Respir J. 8:834–842. 1995.PubMed/NCBI
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Van Rooij E and Olson EN: MicroRNAs:
Powerful new regulators of heart disease and provocative
therapeutic targets. J Clin Invest. 117:2369–2376. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Cushing L, Kuang PP, Qian J, Shao F, Wu J,
Little F, Thannickal VJ, Cardoso WV and Lü J: miR-29 is a major
regulator of genes associated with pulmonary fibrosis. Am J Respir
Cell Mol Biol. 45:287–294. 2011. View Article : Google Scholar :
|
16
|
Guo L, Ji X, Yang S, Hou Z, Luo C, Fan J,
Ni C and Chen F: Genome-wide analysis of aberrantly expressed
circulating miRNAs in patients with coal workers' pneumoconiosis.
Mol Biol Rep. 40:3739–3747. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Tomankova T, Petrek M and Kriegova E:
Involvement of microRNAs in physiological and pathological
processes in the lung. Respir Res. 11:1592010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Oglesby IK, McElvaney NG and Greene CM:
MicroRNAs in inflammatory lung disease-master regulators or target
practice? Respir Res. 11:1482010. View Article : Google Scholar
|
19
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PloS one. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Yang J, Liu H, Wang H and Sun Y:
Down-regulation of microRNA-181b is a potential prognostic marker
of non-small cell lung cancer. Pathol Res Pract. 209:490–494. 2013.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Sato T, Liu X, Nelson A, Nakanishi M,
Kanaji N, Wang X, Kim M, Li Y, Sun J, Michalski J, et al: Reduced
miR-146a increases prostaglandin E2 in chronic
obstructive pulmonary disease fibroblasts. Am J Respir Crit Care
Med. 182:1020–1029. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Faxuan W, Qin Z, Dinglun Z, Tao Z, Xiaohui
R, Liqiang Z and Yajia L: Altered microRNAs expression profiling in
experimental silicosis rats. J Toxicol Sci. 37:1207–1215. 2012.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Urbich C, Kuehbacher A and Dimmeler S:
Role of microRNAs in vascular diseases, inflammation and
angiogenesis. Cardiovasc Res. 79:581–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Nakasa T, Miyaki S, Okubo A, Hashimoto M,
Nishida K, Ochi M and Asahara H: Expression of microRNA-146 in
rheumatoid arthritis synovial tissue. Arthritis Rheum.
58:1284–1292. 2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Li L, Chen XP and Li YJ: MicroRNA-146a and
Human Disease. Scand J Immunol. 71:227–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
26
|
Cameron JE, Yin Q, Fewell C, Lacey M,
McBride J, Wang X, Lin Z, Schaefer BC and Flemington EK:
Epstein-Barr virus latent membrane protein 1 induces cellular
MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J
Virol. 82:1946–1958. 2008. View Article : Google Scholar :
|
27
|
Stanczyk J, Pedrioli DM, Brentano F,
Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S and Kyburz
D: Altered expression of MicroRNA in synovial fibroblasts and
synovial tissue in rheumatoid arthritis. Arthritis Rheum.
58:1001–1009. 2008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Perry MM, Williams AE, Tsitsiou E,
Larner-Svensson HM and Lindsay MA: Divergent intracellular pathways
regulate interleukin-1beta-induced miR-146a and miR-146b expression
and chemokine release in human alveolar epithelial cells. FEBS
Lett. 583:3349–3355. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Liu X, Nelson A, Wang X, Kanaji N, Kim M,
Sato T, Nakanishi M, Li Y, Sun J, Michalski J, et al: MicroRNA-146a
modulates human bronchial epithelial cell survival in response to
the cytokine-induced apoptosis. Biochem Biophys Res Commun.
380:177–182. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhong T, Perelman JM, Kolosov VP and Zhou
XD: MiR-146a negatively regulates neutrophil elastase-induced
MUC5AC secretion from 16HBE human bronchial epithelial cells. Mol
Cell Biochem. 358:249–255. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Sato T, Liu X, Nelson A, Nakanishi M,
Kanaji N, Wang X, Kim M, Li Y, Sun J, Michalski J, et al: Reduced
miR-146a increases prostaglandin E2 in chronic
obstructive pulmonary disease fibroblasts. Am J Respir Crit Care
Med. 182:1020–1029. 2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Ma X, Becker Buscaglia LE, Barker JR and
Li Y: MicroRNAs in NF-kapppaB signaling. J Mol Cell Biol.
3:159–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Taganov KD, Boldin MP, Chang KJ and
Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an
inhibitor targeted to signaling proteins of innate immune
responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Carroll AP, Tran N, Tooney PA and Cairns
MJ: Alternative mRNA fates identified in microRNA-associated
transcriptome analysis. BMC Genomics. 13:5612012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Visone R, Veronese A, Rassenti LZ, Balatti
V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ and Croce
CM: miR-181b is a biomarker of disease progression in chronic
lymphocytic leukemia. Blood. 118:3072–3079. 2011. View Article : Google Scholar : PubMed/NCBI
|
36
|
Sun X, Icli B, Wara AK, Belkin N, He S,
Kobzik L, Hunninghake GM, Vera MP; MICU Registry; Blackwell TS, et
al: MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J
Clin Invest. 122:1973–1990. 2012.PubMed/NCBI
|
37
|
Visone R, Veronese A, Balatti V and Croce
CM: MiR-181b: New perspective to evaluate disease progression in
chronic lymphocytic leukemia. Oncotarget. 3:195–202. 2012.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Chen L, Yang Q, Kong WQ, Liu T, Liu M, Li
X and Tang H: MicroRNA-181b targets cAMP responsive element binding
protein 1 in gastric adenocarcinomas. IUBMB Life. 64:628–635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu
P, Wei J, Jiang K and Miao Y: miRNA-181b increases the sensitivity
of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro
and in nude mice by targeting BCL-2. Oncol Rep. 29:1769–1776.
2013.PubMed/NCBI
|
40
|
Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang
YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly
enhances drug sensitivity in chronic lymphocytic leukemia cells via
targeting multiple anti-apoptosis genes. Carcinogenesis.
33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|